Yes, a significant cost AND it would not only need to address the solubility issue which held back RC110, but also need to notably outperform RC220 to be viable for trials and commercilisation.
Could Bisantrene be tweaked further? Perhaps. Race Oncology is already doing this in the background, namely for potential FTO opportunities.
Yes, a significant cost AND it would not only need to address...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
0.005(0.28%) |
Mkt cap ! $305.0M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.84 | $1.79 | $111.6K | 61.34K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2410 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 5815 | 2 |
View Market Depth
| Last trade - 13.22pm 01/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |